This proposal requests support for years 36-40 of the University of Virginia Cancer Training Program. This Program seeks to bring together faculty and trainees who have common interests in cancer biology to (1) develop a greater understanding of the systems and processes that drive tumor initiation, growth, progression, and metastasis and (2) identify and exploit novel and potentially tumor-specific therapeutic targets. In parallel, the Program provides basic researchers with exposure to the physical, clinical, and psychosocial aspects of cancer through its close ties with the Cancer Center. Its overall objective is thus to provide predoctoral and postdoctoral fellows with a training platform that meets the dual goals of generating new information regarding the etiologies, progression, and treatment of cancer and preparing the next generation of young investigators for careers in cancer research. The Program supports 9 predoctoral and 4 postdoctoral trainees through a curriculum that includes didactic coursework, high quality research, a number of programmatic activities including an annual retreat, clinical/translational exposures through attendance at organ-based tumor boards, and outreach activities. Forty nine (49) mentors comprise the training faculty;collectively, these faculty are exceptionally accomplished cancer researchers, mentors, and teachers. Four goals for the next grant period provide the framework for this renewal application: (1) to build on the strengths of a program that has grown and matured in parallel with the rapidly growing field that is cancer research;(2) to invigorate and infuse new energy into the program through exposure to the most cutting-edge science and scientists (both young and old) who are leaders in their respective fields;(3) to provide future cancer researchers with the intellectual and problem-solving skills to become life-learners in a field tha is continually evolving;and (4) to promote translational research founded on a platform of strong basic science and discovery. The Cancer Training Program has experienced much success over its 34-year history, having trained hundreds of young scientists in cancer research who now have successful careers in academia, industry, and education. As we move into this next funding period, we challenge ourselves not to merely continue along a path that has been historically successful, but to """"""""push the envelope,"""""""" be creative in our course offerings and teaching modalities, provide an even richer research and clinical environment than already exists, integrate with cancer training programs at other institutions to maximize resources and opportunity, and assimilate our clinical colleagues into every component of the training program. The program details outlined herein, and the proposed changes for the coming grant period, reflect the commitment of our training faculty to provide our trainees with a highly creative and vibrant training program, one that will both entice and prepare them for careers in cancer research.

Public Health Relevance

The Cancer Training Program described herein is designed to prepare the next generation of young investigators for careers in cancer research. By providing them with the practical skills to perform the research, the foundational knowledge to initiate a process of life-long learning, and the experience of being part of a dynamic and interactive research team, our trainees will be uniquely prepared to make inroads into understanding and curing cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009109-38
Application #
8690778
Study Section
Special Emphasis Panel (ZCA1-RTRB-K (O1))
Program Officer
Damico, Mark W
Project Start
1976-07-01
Project End
2017-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
38
Fiscal Year
2014
Total Cost
$580,601
Indirect Cost
$33,553
Name
University of Virginia
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Stellfox, Madison E; Nardi, Isaac K; Knippler, Christina M et al. (2016) Differential Binding Partners of the Mis18α/β YIPPEE Domains Regulate Mis18 Complex Recruitment to Centromeres. Cell Rep 15:2127-35
Mauldin, Ileana S; Wages, Nolan A; Stowman, Anne M et al. (2016) Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. Cancer Immunol Immunother 65:1201-12
Mauldin, Ileana S; Wages, Nolan A; Stowman, Anne M et al. (2016) Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. Cancer Immunol Immunother 65:1189-99
Cross, A M; Wilson, A L; Guerrero, M S et al. (2016) Breast cancer antiestrogen resistance 3-p130(Cas) interactions promote adhesion disassembly and invasion in breast cancer cells. Oncogene 35:5850-5859
Andersson, E; Kuusanmäki, H; Bortoluzzi, S et al. (2016) Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia. Leukemia 30:1204-8
Slingluff Jr, Craig L; Petroni, Gina R; Olson, Walter C et al. (2016) A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites. Cancer Immunol Immunother 65:25-36
Heo, Jinho; Eki, Rebeka; Abbas, Tarek (2016) Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis. Semin Cancer Biol 36:33-51
Griner, Erin M; Dancik, Garrett M; Costello, James C et al. (2015) RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer. Mol Cancer Res 13:483-92
Healy, Marin E; Chow, Jenny D Y; Byrne, Frances L et al. (2015) Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine. J Hepatol 62:599-606
Rajala, Hanna L M; Olson, Thomas; Clemente, Michael J et al. (2015) The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. Haematologica 100:91-9

Showing the most recent 10 out of 130 publications